Metagenomi Therapeutics, Inc. Common Stock (MGX) Stock Price

MGXStock

$1.19−36.36%52W

Market Cap$44.95M

P/E—

PEG Ratio—

Div yield—

Beta0.67

MGX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.60%

Price vs S&P 500 (4W)-3.19%

VGM Score44.54

Book Value / Share (Quarterly)$3.66

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)13.59%

Cash Flow / Share (Quarterly)$-2.33

Price vs S&P 500 (YTD)-39.36%

Net Profit Margin (TTM)-384.61%

EPS (TTM)$-2.30

10-Day Avg Trading Volume0.14M

EPS Excl Extra (TTM)$-2.30

EPS (Annual)$-2.36

ROI (Annual)-55.40%

Net Profit Margin (5Y Avg)-1945.52%

Cash / Share (Quarterly)$3.72

Revenue Growth QoQ (YoY)-69.76%

ROA (Last FY)-39.74%

Revenue Growth TTM (YoY)-50.66%

EBITD / Share (TTM)$-2.34

ROE (5Y Avg)-37.04%

Operating Margin (TTM)-415.48%

Cash Flow / Share (Annual)$-2.38

P/B Ratio0.34x

P/B Ratio (Quarterly)0.37x

Net Income / Employee (Annual)$-738,400

EV / Revenue (TTM)0.95x

ROA (TTM)-36.62%

EPS Incl Extra (Annual)$-2.36

Current Ratio (Annual)7.22x

Quick Ratio (Quarterly)6.23x

3-Month Avg Trading Volume0.16M

52-Week Price Return-36.36%

Revenue / Employee (TTM)$187,700

P/S Ratio (Annual)1.84x

Asset Turnover (Annual)0.11x

52-Week High$3.95

Operating Margin (5Y Avg)-2168.10%

EPS Excl Extra (Annual)$-2.36

26-Week Price Return-20.67%

Quick Ratio (Annual)7.03x

13-Week Price Return-15.00%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)6.43x

Enterprise Value$21.16M

Asset Turnover (TTM)0.10x

Revenue / Employee (Annual)$211,800

Pretax Margin (Annual)-348.77%

Cash / Share (Annual)$4.27

3-Month Return Std Dev37.03%

Net Income / Employee (TTM)$-721,700

ROE (Last FY)-55.40%

EPS Basic Excl Extra (Annual)$-2.36

Receivables Turnover (TTM)44.13x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.30

Receivables Turnover (Annual)32.28x

ROI (TTM)-51.23%

P/S Ratio (TTM)2.08x

Pretax Margin (5Y Avg)-1941.11%

Revenue / Share (Annual)$0.68

Price vs S&P 500 (52W)-54.92%

Year-to-Date Return-26.54%

5-Day Price Return-1.65%

EPS Normalized (Annual)$-2.36

ROA (5Y Avg)-21.62%

Net Profit Margin (Annual)-348.54%

Month-to-Date Return0.00%

EBITD / Share (Annual)$-2.43

Operating Margin (Annual)-380.85%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-33.06%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.30

P/B Ratio (Annual)0.38x

Pretax Margin (TTM)-385.27%

Book Value / Share (Annual)$4.22

Price vs S&P 500 (13W)-16.95%

Beta0.67x

P/FCF (Annual)2.95x

Revenue / Share (TTM)$0.59

ROE (TTM)-51.23%

52-Week Low$1.13

vGradeA

gGradeF

mGradeD

vgmGradeC

MGX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 10, 2026	-$0.52	-$0.73	-40.38%(-$0.21)
Q1 2026	May 11, 2026	-$0.55	-$0.61	-10.91%(-$0.06)
Q4 2025	Mar 5, 2026	-$0.58	-$0.60	-2.56%(-$0.02)
Q3 2025	Nov 11, 2025	-$0.53	-$0.55	-3.13%(-$0.02)
Q2 2025	Aug 12, 2025	-$0.62	-$0.54	+13.01%(+$0.08)

MGX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.00

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
MGXMetagenomi Therapeutics, Inc. Common Stock	A	F	D	$1.19
AMGNAmgen Inc	C	C	B	$432.42
GILDGilead Sciences Inc	C	B	B	$145.68
ARGXargenx SE American Depositary Shares	D	A	B	$1023.21
MRNAModerna, Inc. Common Stock	D	C	A	$137.99
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$207.88
BIIBBiogen Inc. Common Stock	C	D	B	$218.50
BNTXBioNTech SE American Depositary Share	C	C	C	$102.08
NBIXNeurocrine Biosciences Inc	C	B	C	$154.06
EXELExelixis Inc	C	B	B	$54.45
HALOHalozyme Therapeutics, Inc.	C	B	B	$105.35
TECHBio-Techne Corp.	D	C	B	$72.35
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$351.46
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.97
RGENRepligen Corp	D	C	B	$176.27
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$118.15
PCVXVaxcyte, Inc. Common Stock	—	—	B	$59.84
QGENQIAGEN N.V.	C	C	B	$43.11
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$141.38
IBRXImmunityBio, Inc. Common Stock	F	A	B	$8.05
IMVTImmunovant, Inc. Common Stock	—	—	B	$41.20
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$57.80
CGONCG Oncology, Inc. Common stock	F	A	B	$74.34
CRSPCRISPR Therapeutics AG	D	B	C	$57.72
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	$18.77
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$25.19
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.00
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.01
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.76
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$29.32
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.82
KODKodiak Sciences Inc Common Stock	—	—	B	$37.72
MESOMesoblast Limited American Depositary Shares	D	B	B	$17.44
VCELVericel Corporation	D	B	B	$40.95
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$44.84
ADMAADMA Biologics, Inc.	C	C	C	$9.34
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$36.62
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$5.77
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.83
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	$123.41
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.34
ALVOAlvotech Ordinary Shares	C	D	C	$4.95
NVAXNovavax Inc	B	D	C	$9.26
MAZEMaze Therapeutics, Inc. Common Stock	—	—	C	$27.44
SLBTSL Science Holding Limited Ordinary Shares	—	—	C	$2.70
REPLReplimune Group, Inc.	—	—	A	$15.50
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.45
VORVor Biopharma Inc. Common Stock	—	—	B	$22.65
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$21.70
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	B	$13.82
SANASana Biotechnology, Inc. Common Stock	—	—	B	$3.93

About Metagenomi Therapeutics, Inc. Common Stock

Metagenomi Therapeutics is a genetic medicines company developing in vivo gene editing therapies using its proprietary metagenomics-derived platform. The company's pipeline targets hemophilia A, refractory hypertension, and cardiovascular diseases. Its comprehensive editing toolbox includes programmable nucleases, base editors, and CRISPR-associated transposases, with the company also pursuing technology licensing for ex vivo cell therapy applications.